Professor Chim Lang
Molecular and Clinical Medicine, School of Medicine
+44 (0)1382 383283
Ninewells - Mailbox 2
Professor Lang is a consultant cardiologist and clinical pharmacologist and Professor of Cardiology at Ninewells Hospital and Medical School, Dundee, United Kingdom.
He trained in both cardiology and clinical pharmacology in the United Kingdom and in the United States where he was a Merck International Fellow in Clinical Pharmacology at Vanderbilt University, Nashville and a Fulbright Scholar at Columbia University, New York. He is a Fellow of the Royal Colleges of Physicians of London and Edinburgh and the American College of Cardiology and European Society of Cardiology.
- The eyes have it as Dundee University heads artificial intelligence project - Dundee Courier
- Cheap Drug to defeat heart disease - Express
- Retinal Scans Provide Heart Failure Warning Signals - Labmate
- Diabetic drug shown to reduce the risk of heart disease in non-diabetic patients - EurekAlert
- Drug used to treat type 2 diabetes could also reduce heart disease - Diabetic Research and Wellness Foundation
- Call for ‘less aggressive’ diabetes treatment - Diabetes Times
- Good HbA1c levels could benefit type 2 diabetes patients with chronic heart failure, study finds - Diabetes.co.uk
Professor Lang is a translational cardiologist with a track record of research excellence in the area of cardio-metabolic diseases. He has published >250 papers in major journals, including NEJM, Lancet, European Heart Journal, JACC and Circulation.
His research takes a multi-disciplinary approach to the understanding of the pathophysiology and pharmacogenetics of cardiovascular diseases and to the development of treatment strategies in patients with cardiovascular diseases. He leads an integrated cardiovascular research laboratory dedicated and equipped to the study of cardiac and vasomotor regulation. These techniques are applied towards translational research and in the development of biomarkers and novel treatment strategies in patients with cardiovascular diseases.
Prof Lang is WP Co-Lead in the €12.3M IMI2-CARDIATEAM project on diabetic cardiomyopathy and was WP lead in the €11.9M FP-7 BIOSTAT system biology project on heart failure and is the Chief Investigator of the BHF funded MET-REMODEL and RECEDE trials and the EFSD funded REFORM trial.
He is also the lead Applicant of the MRC funded MRC UK-Malaysia Partnership on the Precision medicine for diabetic Individuals: a joint Malaysia-UK Effort (PRIME) project. He is the UK National Coordinator of the multi-international COMMANDER-HF and SELECT trials.
A wide range of funding bodies including the British Heart Foundation, MRC, Chief Scientist Office, EASD, Chest Heart and Stroke Scotland, Tenovus and the European commission Seventh Framework (FP-7) and Horizon 2020 Programmes funds his research.
Full contribution to teaching in Dundee, especially cardiology and clinical pharmacology. External undergraduate examinerships (National University of Singapore, University of Malaya, International Medical University, Malaysia, National University of Malaysia). Supervisor of 25 MD/PhDs personally. External examiner for PhD/ MD (Universities of Birmingham, Cardiff, Edinburgh, Glasgow, Aberdeen, Hull)
The commonly used diabetes drug metformin could reverse the harmful thickening of heart muscle that leads to cardiovascular disease, according to a study at the University of Dundee
Retinal scans studied by advanced artificial intelligence could warn people living with diabetes if they are at risk of heart failure